Bdsi Drug Patent Portfolio
Bdsi owns 3 orange book drugs protected by 14 US patents Given below is the list of Bdsi's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9522188 | Abuse resistant transmucosal drug delivery device | 24 Apr, 2035 | Active |
| US10952968 | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives | 13 May, 2033 | Active |
| US12350377 | Preparation Containing 6,7-Unsaturated-7-Carbamoyl Morphinan Derivatives | 13 May, 2033 | Active |
| US9901539 | Transmucosal drug delivery devices for use in chronic pain relief | 21 Dec, 2032 | Active |
| US8703177 | Abuse-resistant mucoadhesive devices for delivery of buprenorphine | 20 Aug, 2032 | Active |
| US9108975 | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same | 11 Nov, 2031 | Active |
| USRE46365 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | 24 Feb, 2031 | Active |
| US8084460 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | 11 Jan, 2028 | Active |
| US8147866 | Transmucosal delivery devices with enhanced uptake | 23 Jul, 2027 | Active |
| US9655843 | Transmucosal delivery devices with enhanced uptake | 23 Jul, 2027 | Active |
| US8536192 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | 05 Oct, 2026 | Active |
| USRE46375 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | 05 Oct, 2026 | Active |
| US7579019 | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces | 22 Jan, 2020 | Expired |
| US6159498 | Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces | 18 Oct, 2016 | Expired |
Latest Legal Activities on Bdsi's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Bdsi.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Aug, 2025 | US9901539 |
| Recordation of Patent Grant Mailed | 15 Jul, 2025 | US12350377 |
| Patent eGrant Notification | 08 Jul, 2025 | US12350377 |
| Email Notification | 08 Jul, 2025 | US12350377 |
| Recordation of Patent eGrant | 08 Jul, 2025 | US12350377 |
| Mail Patent eGrant Notification | 08 Jul, 2025 | US12350377 |
| Patent Issue Date Used in PTA Calculation | 08 Jul, 2025 | US12350377 |
| Email Notification | 26 Jun, 2025 | US12350377 |
| Issue Notification Mailed | 25 Jun, 2025 | US12350377 |
| Application Is Considered Ready for Issue | 06 Jun, 2025 | US12350377 |
| Dispatch to FDC | 06 Jun, 2025 | US12350377 |
| Issue Fee Payment Verified | 04 Jun, 2025 | US12350377 |
| Issue Fee Payment Received | 04 Jun, 2025 | US12350377 |
| Mail Notice of Allowance | 18 Apr, 2025 | US12350377 |
| Notice of Allowance Data Verification Completed | 16 Apr, 2025 | US12350377 |
Bdsi's Drug Patent Litigations
Bdsi's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 22, 2014, against patent number US7579019. The petitioner MONOSOL RX, LLC, challenged the validity of this patent, with Arius Two, Inc. et al. as the respondent. Click below to track the latest information on how companies are challenging Bdsi's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9522188 | December, 2012 |
Decision
(29 Jan, 2016)
| Andrew Finn et al | |
| US7579019 | January, 2014 |
Final Written Decision
(05 Aug, 2015)
| Arius Two, Inc. et al. | MONOSOL RX, LLC |
Bdsi's Family Patents
Bdsi Drug List
Given below is the complete list of Bdsi's drugs and the patents protecting them.
1. Belbuca
Belbuca is protected by 5 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9901539 | Transmucosal drug delivery devices for use in chronic pain relief |
21 Dec, 2032
(6 years from now)
| Active |
| US8147866 | Transmucosal delivery devices with enhanced uptake |
23 Jul, 2027
(1 year, 4 months from now)
| Active |
| US9655843 | Transmucosal delivery devices with enhanced uptake |
23 Jul, 2027
(1 year, 4 months from now)
| Active |
| US7579019 | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
22 Jan, 2020
(6 years ago)
| Expired |
| US6159498 | Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces |
18 Oct, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Belbuca's drug page
2. Bunavail
Bunavail is protected by 6 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9522188 | Abuse resistant transmucosal drug delivery device |
24 Apr, 2035
(9 years from now)
| Active |
| US8703177 | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
20 Aug, 2032
(6 years from now)
| Active |
| US8147866 | Transmucosal delivery devices with enhanced uptake |
23 Jul, 2027
(1 year, 4 months from now)
| Active |
| US9655843 | Transmucosal delivery devices with enhanced uptake |
23 Jul, 2027
(1 year, 4 months from now)
| Active |
| US7579019 | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
22 Jan, 2020
(6 years ago)
| Expired |
| US6159498 | Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces |
18 Oct, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bunavail's drug page
3. Symproic
Symproic is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10952968 | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives |
13 May, 2033
(7 years from now)
| Active |
| US12350377 | Preparation Containing 6,7-Unsaturated-7-Carbamoyl Morphinan Derivatives |
13 May, 2033
(7 years from now)
| Active |
| US9108975 | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same |
11 Nov, 2031
(5 years from now)
| Active |
| USRE46365 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
24 Feb, 2031
(4 years from now)
| Active |
| US8084460 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
11 Jan, 2028
(1 year, 9 months from now)
| Active |
| US8536192 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
05 Oct, 2026
(6 months from now)
| Active |
| USRE46375 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
05 Oct, 2026
(6 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Symproic's drug page